Title:Pioneering the Battle Against Breast Cancer: The Promise of New Bcl-2 Family
Volume: 25
Issue: 3
Author(s): Ali Farhang Boroujeni and Zeynep Ates-Alagoz*
Affiliation:
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey
Keywords:
Bcl-2 family inhibitors, Bcl-xL, Mcl-1, Bcl-2, synthetic scaffolds, breast cancer.
Abstract: Currently, breast cancer is the most common cancer type, accounting for 1 in every 4 cancer cases.
Leading both in mortality and incidence, breast cancer causes 1 in 4 cancer deaths. To decrease the burden of
breast cancer, novel therapeutic agents which target the key hallmarks of cancer, are being explored. The Bcl-2
family of proteins has a crucial role in governing cell death, making them an attractive target for cancer therapy.
As cancer chemotherapies lead to oncogenic stress, cancer cells upregulate the Bcl-2 family to overcome apoptosis,
leading to failure of treatment. To fix this issue, Bcl-2 family inhibitors, which can cause cell death, have
been introduced as novel therapeutic agents. Members of this group have shown promising results in in-vitro
studies, and some are currently in clinical trials. In this review, we will investigate Bcl-2 family inhibitors, which
are already in trials as monotherapy or combination therapy for breast cancer, and we will also highlight the result
of in vitro studies of novel Bcl-2 family inhibitors on breast cancer cells. The findings of these studies have yielded
encouraging outcomes regarding the identification of novel Bcl-2 family inhibitors. These compounds hold
significant potential as efficacious agents for employment in both monotherapy and combination therapy settings.